Neurelis vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Neuroscience pharma commercializing VALTOCO (diazepam nasal spray) for seizure clusters. ~$295-300M estimated net sales in 2025; 30%+ EBITDA margin; no bank debt.
About
Neurelis is a private neuroscience-focused pharmaceutical company dedicated to developing and commercializing therapies for epilepsy and neurological disorders. Its lead commercial product, VALTOCO (diazepam nasal spray), is an FDA-approved treatment for acute seizure clusters in patients aged two and older — a label expansion to children ages two to five was approved in April 2025. The company reported estimated net sales of $295–300 million for 2025, more than doubling 2024 revenue, with an EBITDA margin exceeding 30% and a debt-free balance sheet holding $175M+ in cash. VALTOCO''s Orange Book patent portfolio now includes six listed patents, extending exclusivity to October 2032. Neurelis is using this commercial momentum to advance its CNS pipeline and pursue additional products.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.